Form 4: Laith L. Yaldoo Reports Acquisition of Zivo Bioscience Shares
SEC Form 4 Filing
Director and 10% owner Laith L. Yaldoo reports acquiring additional shares of Zivo Bioscience, Inc. common stock through non-cash transactions.
Summary
- On January 1, 2025, Laith L. Yaldoo, a director and 10% owner of Zivo Bioscience, Inc., acquired 5,382 shares of common stock.
- On the same day, Yaldoo acquired an additional 5,740 shares of common stock.
- Both transactions were acquisitions (A) with a price of $0.
- Following these transactions, Yaldoo directly owns 542,111 shares of Zivo Bioscience, Inc.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it simply reports a transaction. The acquisition could be seen as positive, but without further context, it's difficult to assess the overall impact.
Positives
- The increased holdings could be interpreted as a sign of confidence in the company's future prospects by a key insider.
Industry Context
This filing is a routine disclosure required by the SEC for insider transactions. It provides transparency regarding the holdings and transactions of company insiders.
Stakeholder Impact
- Shareholders may view the insider's increased stake as a positive signal.
Key Dates
| Date | Description |
|---|---|
| 01/01/2025 | Date of common stock acquisition (5,382 shares) |
| 01/01/2025 | Date of common stock acquisition (5,740 shares) |
| 01/03/2025 | Date of signature for the Form 4 filing |
Keywords
Zivo Bioscience, Insider Trading, Form 4, Beneficial Ownership, Laith L. Yaldoo, Share Acquisition, Director, 10% Owner
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.